Atypical presentation of metastatic disease in patients with stage 4S neuroblastoma of the observation group: description of the clinical case-Reference-Cited by-同舟云学术

Atypical presentation of metastatic disease in patients with stage 4S neuroblastoma of the observation group: description of the clinical case

Published:2020-09-21 Issue:3 Volume:7 Page:125-131
ISSN:2413-5496
Container-title:Russian Journal of Pediatric Hematology and Oncology
language:
Short-container-title:Ross. ž. det. gematol. onkol.

Author:

Smirnova L. A.¹^ORCID,Kachanov D. Yu.¹^ORCID,Shcherbakov A. P.¹^ORCID,Akhaladze D. G.¹^ORCID,Teleshova M. V.¹^ORCID,Likar Yu. N.¹^ORCID,Shamanskaya T. V.¹^ORCID

Affiliation:

1. Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia

Abstract

The most common extracranial solid malignant tumor of childhood – neuroblastoma (NB) is characterized by the presence of two metastatic forms (stages 4 and 4S). Stage 4S is described to have metastatic spread to the liver, skin, and minimal bone marrow invasion. Certain rare localisations of NB metastases (pleura, testicles, and others) may not worsen the prognosis in children of the first year of life in the absence of severe bone marrow invasion and metastases to the skeletal bones. The article describes a clinical case of retroperitoneal NB with atypical metastasis to the pleura in a child of the first months of life with a favorable outcome with a minimum amount of chemotherapy.

Publisher

OOO Grafika

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference15 articles.

1. Shamanskaya T.V., Kachanov D.Yu., Feoktistova E.V., Tereshchenko G.V., Likar Yu.N., Muftakhova G.M., Talypov S.R., Varfolomeeva S.R. Heterogeneity of neuroblastoma stage 4S: a multidisciplinary view. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2017;4(1):83–8. (In Russ.). doi: 10.17650/2311-1267-2017-4-1-83-88.

2. Brodeur G.M., Pritchard J., Berthold F., Carlsen N.L., Castel V., Castleberry R.P., Bernardi B.D., Evans A. E., Favrot M.C., Hedborg F., Kaneko M., Kemshead J., Lampert F., Lee R.J., Look A.T., Pearson A.D., Philip T., Roald B., Sawada T., Seeger R.C., Tsuchida Y., Voute P.A. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11(8):1466–77. doi: 10.1200/JCO.1993.11.8.1466.

3. Pritchard J., Hickman J.A. Why does stage 4s neuroblastoma regress spontaneously? Lancet 1994;344(8926):869–70. doi: 10.1016/S0140-6736(94)92834-7.

4. van Noesel M.M., Hählen K., Hakvoort-Cammel F.G., Egeler R.M. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. Cancer 1997;80(5):834–43. PMID: 9307181.

5. Monclair T., Brodeur G.M., Ambros P.F., Brisse H.J., Cecchetto G., Holmes K., Kaneko M., London W.B., Matthay K.K., Nuchtern J.G., von Schweinitz D., Simon T., Cohn S.L., Pearson A.D.J.; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27(2):298–303. doi: 10.1200/JCO.2008.16.6876.